|
|
|
Volumn 103, Issue 1, 2001, Pages
|
|
Gene therapists promise renewed vigor in monitoring as field progresses.
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ARTICLE;
FOOD AND DRUG ADMINISTRATION;
GENE THERAPY;
GENE VECTOR;
HEALTH CARE ORGANIZATION;
HUMAN;
LEGAL ASPECT;
MEDICAL SOCIETY;
MULTIPLE ORGAN FAILURE;
PROFESSIONAL PRACTICE;
STANDARD;
UNITED STATES;
BLEEDING;
CEREBROVASCULAR ACCIDENT;
DRUG ANTAGONISM;
HEART INFARCTION;
ORAL DRUG ADMINISTRATION;
PHASE 3 CLINICAL TRIAL;
TREATMENT OUTCOME;
GENE THERAPY;
GENETIC VECTORS;
HUMANS;
MULTIPLE ORGAN FAILURE;
NATIONAL INSTITUTES OF HEALTH (U.S.);
PROFESSIONAL AUTONOMY;
SOCIETIES, MEDICAL;
UNITED STATES;
UNITED STATES FOOD AND DRUG ADMINISTRATION;
ADMINISTRATION, ORAL;
BENZODIAZEPINES;
CEREBROVASCULAR ACCIDENT;
CLINICAL TRIALS, PHASE III;
HEMORRHAGE;
MYOCARDIAL INFARCTION;
PIPERIDINES;
PLATELET AGGREGATION INHIBITORS;
PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX;
TREATMENT OUTCOME;
ANTITHROMBOCYTIC AGENT;
BENZODIAZEPINE DERIVATIVE;
FIBRINOGEN RECEPTOR;
LOTRAFIBAN;
PIPERIDINE DERIVATIVE;
|
|
EID: 0035793182
PISSN: 15244539
EISSN: None
Source Type: Journal
DOI: None Document Type: Article |
|
Times cited : (6)
|
|
References (0)
|
